| Journey Of Hope | |
|
37875 W 12 Mile Rd Ste 203 Farmington Hills MI 48331-3053 | |
| (248) 921-4614 | |
| Not Available |
| Full Name | Journey Of Hope |
|---|---|
| Speciality | Social Worker |
| Location | 37875 W 12 Mile Rd Ste 203, Farmington Hills, Michigan |
| Authorized Official Name and Position | Marie A Schluter (DIRECTOR) |
| Authorized Official Contact | 2489214614 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Journey Of Hope 24773 Reeds Pointe Dr Novi MI 48374-2537 Ph: (248) 921-4614 | Journey Of Hope 37875 W 12 Mile Rd Ste 203 Farmington Hills MI 48331-3053 Ph: (248) 921-4614 |
| NPI Number | 1649891607 |
|---|---|
| Provider Enumeration Date | 04/30/2020 |
| Last Update Date | 04/30/2020 |
| Certification Date | 04/30/2020 |
| Medicare PECOS PAC ID | 3173941820 |
|---|---|
| Medicare Enrollment ID | O20200914001047 |
News Archive
Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
Cases of the Zika virus, a mosquito-transmitted infection that may be linked to birth defects, are on the rise. Currently the majority of cases have been reported in the Americas, with Brazil reporting the highest numbers of cases. Although no local mosquito-borne cases have been reported in the United States, the Centers for Disease Control and Prevention has reported there have been travel-associated cases.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649891607 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 104100000X | Social Worker | (* (Not Available)) | Primary |
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Secondary |
| Provider Name | Monica Johnson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1184808263 PECOS PAC ID: 6608012349 Enrollment ID: I20130424000904 |
News Archive
Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
Cases of the Zika virus, a mosquito-transmitted infection that may be linked to birth defects, are on the rise. Currently the majority of cases have been reported in the Americas, with Brazil reporting the highest numbers of cases. Although no local mosquito-borne cases have been reported in the United States, the Centers for Disease Control and Prevention has reported there have been travel-associated cases.
› Verified 5 days ago
| Provider Name | Marie Agatha Schluter |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1114548385 PECOS PAC ID: 2264850817 Enrollment ID: I20210125002222 |
News Archive
Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
Cases of the Zika virus, a mosquito-transmitted infection that may be linked to birth defects, are on the rise. Currently the majority of cases have been reported in the Americas, with Brazil reporting the highest numbers of cases. Although no local mosquito-borne cases have been reported in the United States, the Centers for Disease Control and Prevention has reported there have been travel-associated cases.
› Verified 5 days ago
| Provider Name | Elaine Terese Plotzke |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1487358164 PECOS PAC ID: 9739541079 Enrollment ID: I20230817002170 |
News Archive
Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
Cases of the Zika virus, a mosquito-transmitted infection that may be linked to birth defects, are on the rise. Currently the majority of cases have been reported in the Americas, with Brazil reporting the highest numbers of cases. Although no local mosquito-borne cases have been reported in the United States, the Centers for Disease Control and Prevention has reported there have been travel-associated cases.
› Verified 5 days ago
News Archive
Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
Cases of the Zika virus, a mosquito-transmitted infection that may be linked to birth defects, are on the rise. Currently the majority of cases have been reported in the Americas, with Brazil reporting the highest numbers of cases. Although no local mosquito-borne cases have been reported in the United States, the Centers for Disease Control and Prevention has reported there have been travel-associated cases.
› Verified 5 days ago
Words Of Wellness Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 33730 Freedom Rd, Suite C, Farmington Hills, MI 48335 Phone: 248-675-5131 | |
Trinity Health Connections, Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 25882 Orchard Lake Rd, Suite L-5, Farmington Hills, MI 48336 Phone: 248-426-7299 Fax: 248-325-5846 | |
Art Of Healing Behavioral Services, P.l.l.c. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 22111 Atlantic Pointe, Farmington Hills, MI 48336 Phone: 248-514-7919 | |
Michigan Family Therapy, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32841 Middlebelt Rd, Suite 405, Farmington Hills, MI 48334 Phone: 248-733-4899 Fax: 248-733-4208 | |
Serene Counseling And Wellness Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 25521 Arden Park Dr, Farmington Hills, MI 48336 Phone: 313-409-8060 | |
Mindful Development, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 36216 Freedom Rd Ste 27, Farmington Hills, MI 48335 Phone: 734-335-0845 | |
Farmington Hills Center For Child Therapy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 32813 Middlebelt Rd Ste L, Farmington Hills, MI 48334 Phone: 248-626-0478 |